In conclusion, we have shown how the novel mutational signature fitting algorithm mmsig can be applied to identify biologically and clinically important mutational processes acting in hematological cancers, including chemotherapy-related mutational signatures, APOBEC activity in MM and nc-AID in CLL. This evidence concerns the gene AICDA and B-cell chronic lymphocytic leukemia.